BioCentury
ARTICLE | Cover Story

A top-notch inhibitor

November 19, 2009 8:00 AM UTC

University of California, San Diego researchers have identified a role for Notch, a signaling pathway typically associated with cancer, in an entirely new indication-pulmonary arterial hypertension.1 In light of a new way to specifically inhibit Notch signaling described last week by a Harvard Universityteam,2 this previously intractable pathway may now become a more realistic target for a wide range of indications.

Both sets of results are good news for Aileron Therapeutics Inc., which has licensed the Notch targeting platform from Harvard and could now design Notch inhibitors for multiple indications, including cancer and pulmonary disorders...